Myla Puyat
Director of Finance/CFO at Auxogyn, Inc.
Profile
Ms. Myla Puyat is Vice President-Finance & Administration at Auxogyn, Inc. and Vice President-Finance & Administration at Progyny, Inc.
Ms. Puyat was previously employed as a Director-Finance & Administration by ForteBio, Inc., Operations Director & Controller by GeneTrol Biotherapeutics, Inc., and Vice President-Finance & Administration by Verinata Health, Inc.
She received her undergraduate degree from Santa Clara University and an MBA from Santa Clara University.
Myla Puyat active positions
Companies | Position | Start |
---|---|---|
Auxogyn, Inc.
Auxogyn, Inc. BiotechnologyHealth Technology Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA. | Director of Finance/CFO | 2014-06-30 |
Former positions of Myla Puyat
Companies | Position | End |
---|---|---|
PROGYNY, INC. | Director of Finance/CFO | - |
ForteBio, Inc.
ForteBio, Inc. Medical SpecialtiesHealth Technology Pall ForteBio Corp. develops analytical systems that enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The company was founded in October 2001 and is headquartered in Menlo Park, CA. | Director of Finance/CFO | - |
GeneTrol Biotherapeutics, Inc. | Chief Operating Officer | - |
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Director of Finance/CFO | - |
Training of Myla Puyat
Santa Clara University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PROGYNY, INC. | Commercial Services |
Private companies | 4 |
---|---|
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Health Services |
ForteBio, Inc.
ForteBio, Inc. Medical SpecialtiesHealth Technology Pall ForteBio Corp. develops analytical systems that enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The company was founded in October 2001 and is headquartered in Menlo Park, CA. | Health Technology |
GeneTrol Biotherapeutics, Inc. | |
Auxogyn, Inc.
Auxogyn, Inc. BiotechnologyHealth Technology Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA. | Health Technology |
- Stock Market
- Insiders
- Myla Puyat